Leadership Shift at Vetter Signals New Phase in Global GMP Manufacturing Strategy
Ravensburg, Germany — December 3, 2025 — Vetter Pharma-Fertigung GmbH & Co. KG, a global contract development and manufacturing...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Ravensburg, Germany — December 3, 2025 — Vetter Pharma-Fertigung GmbH & Co. KG, a global contract development and manufacturing...
Dateline: November 17, 2025 — Philadelphia, PA & Oxford, UKAdaptimmune Therapeutics plc announced significant Board and Executive Leadership changes,...
